Ocular Therapeutix Inc. [OCUL] Is Still Overvalued at $18.95

Ocular Therapeutix Inc. [OCUL] shares are up more than 368.50% this year and recently increased 0.01% or $0.21 to settle at $18.95. OCUL has a short ratio of 4.67. This implies that the market is currently less bullish on the outlook for OCUL.

On 23, November 2020, Ocular Therapeutix™ to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference. According to news published on Yahoo Finance, Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from December 1 to December 3, 2020.

Analyst Birdseye View:

The most recent analyst activity for Ocular Therapeutix Inc. [NASDAQ:OCUL] stock was on August 10, 2020, when it was Reiterated with a Buy rating from H.C. Wainwright, which also raised its 12-month price target on the stock from $10 to $13. Before that, on November 13, 2020, Raymond James Recapitulated a Strong buy rating and elevated its amount target to $25. On March 03, 2020, Raymond James Upgrade a Strong buy rating. On May 21, 2019, H.C. Wainwright Reiterated a Buy rating and decreased its price target from $12 to $9. On May 21, 2019, Raymond James Downgrade an Outperform rating and decreased its price target to $5. On May 21, 2019, Cowen Downgrade a Market perform rating and boosted its amount target on this stock to $3. On December 03, 2018, Cantor Fitzgerald Reiterated an Overweight rating and boosted its target amount on this stock from $22 to $24. On November 15, 2018 Raymond James Initiated a Strong buy rating and elevated its amount target to $10.

In the past 52 weeks of trading, this stock has oscillated between a low of $3.69 and a peak of $18.86. Right now, according to Wall Street analyst the average 12-month amount target is $15.50. At the most recent market close, shares of Ocular Therapeutix Inc. [NASDAQ:OCUL] were valued at $18.95. According to the average price forecast, investors can expect a potential return of 0.0%.

FUNDAMENTAL ANALYSIS

Ocular Therapeutix Inc. [NASDAQ:OCUL] most recently reported quarterly sales of 5.88 billion, which represented growth of 637.50%. This publicly-traded organization’s revenue is $26,255 per employee, while its income is -$536,472 per employee. This company’s Gross Margin is currently 81.80%, its Pretax Margin is -2043.34, and its Net Margin is -2043.34. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -113.81, -535.72, -147.46 and -149.89 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 106.52 and the whole liability to whole assets at 75.37. It shows enduring liability to the whole principal at 104.49 and enduring liability to assets at 0.74 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 17.81 points at 1st support level, the second support level is making up to 16.87. But as of 1st resistance point, this stock is sitting at 19.27 and at 19.79 for 2nd resistance point.

Ocular Therapeutix Inc. [OCUL] reported its earnings at -$0.21 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.24/share signifying the difference of 0.03 and 12.50% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.64 calling estimates for -$0.31/share with the difference of -0.33 depicting the surprise of -106.50%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Ocular Therapeutix Inc. [NASDAQ:OCUL] is 3.60. Likewise, the Quick ratio is also the same, showing Cash ratio at 4.53. Now if looking for a valuation of this stock’s amount to sales ratio it’s 42.31.

Insider Stories

The most recent insider trade was by SUMMER ROAD LLC, 10% Owner, and it was the purchase of 437.0 shares on Oct 16. SUMMER ROAD LLC, the 10% Owner, completed a purchase of 0.36 million shares on May 19. On Mar 24, SUMMER ROAD LLC, 10% Owner, completed a purchase of 35052.0 shares.